CELC
HEALTHCARECelcuity LLC
AI Insight
What's Moving CELC Today?
No stock-specific AI insight has been generated for CELC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$11.52$151.02
$90.77
Fundamentals
Market Cap$4.3B
P/E Ratio—
EPS$-3.90
Dividend Yield—
Dividend / Share—
ROE-275.2%
Profit Margin—
Debt / Equity—
Trading
Volume404K
Avg Volume (10D)—
Shares Outstanding48.8M
CELC News
26 articles- CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?Stocktwits·Jun 9, 2026
- Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 MillionTradingView·Jun 9, 2026
- Operating expenses (excl. COGS) of Celcuity Inc. – HAM:7VRTradingView·Jun 6, 2026
- Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note OfferingYahoo Finance·Jun 4, 2026
- Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer PatientsYahoo Finance·Jun 4, 2026
- Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032Yahoo Finance·Jun 4, 2026
- US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle EastYahoo Finance·Jun 3, 2026
- Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032Yahoo Finance·Jun 3, 2026
- Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $157Moomoo·Jun 3, 2026
- Celcuity Crashes On Breast Cancer Disappointment. What Happened?Yahoo Finance·Jun 2, 2026
- Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 TrialYahoo Finance·Jun 2, 2026
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialBiopharmadive·Jun 2, 2026
- Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)Advfn·Jun 2, 2026
- Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast CancerYahoo Finance·Jun 2, 2026
- Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026Yahoo Finance·Jun 1, 2026
- Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million MoreMotley Fool·May 30, 2026
- Celcuity To Participate in Upcoming Investor ConferencesYahoo Finance·May 28, 2026
- Delphi Diagnostics Appoints Eric Lindquist as Chief Financial OfficerYahoo Finance·May 19, 2026
- Celcuity Shareholders Approve New 2026 Equity Incentive PlansTipRanks·May 19, 2026
- Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next PhaseMotley Fool·May 17, 2026
- Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesMotley Fool·May 17, 2026
- Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA DecisionYahoo Finance·May 16, 2026
- Celcuity Inc (CELC) Q1 2026 Earnings Call Highlights: Promising Clinical Trials and Strategic ...Yahoo Finance·May 15, 2026
- Celcuity Q1 Earnings Call HighlightsMarketbeat·May 14, 2026
- Why Celcuity Stock Popped on MondayThe Motley Fool·Apr 27, 2026
- Why Celcuity Stock Popped TodayThe Motley Fool·Mar 27, 2026
All 26 articles loaded
Price Data
Open$88.84
Previous Close$89.93
Day High$92.61
Day Low$87.88
52 Week High$151.02
52 Week Low$11.52
52-Week Range
$11.52$151.02
$90.77
Fundamentals
Market Cap$4.3B
P/E Ratio—
EPS$-3.90
Dividend Yield—
Dividend / Share—
ROE-275.2%
Profit Margin—
Debt / Equity—
Trading
Volume404K
Avg Volume (10D)—
Shares Outstanding48.8M
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in Minneapolis, Minnesota.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—